{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(12)"],"submitter":["Singier A"],"pubmed_abstract":["<h4>Importance</h4>Although pharmacovigilance signals and a strong pathophysiological rationale have suggested a potential risk of arterial dissections or aneurysms associated with angiogenesis inhibitors, this association deserves to be further investigated through clinical practice evidence studies.<h4>Objective</h4>To evaluate the association between exposure to angiogenesis inhibitors and the occurrence of arterial dissections or aneurysms in patients treated for metastatic colorectal cancer (mCRC).<h4>Design, setting, and participants</h4>A nested case-control study was conducted within a cohort of adults initiating targeted therapy (angiogenesis or epidermal growth factor receptor inhibitors) for mCRC between January 1, 2012, and December 31, 2017. Data were analyzed from April 2021 "],"journal":["JAMA network open"],"pagination":["e2546960"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12679322"],"repository":["biostudies-literature"],"pubmed_title":["Angiogenesis Inhibitors and Arterial Dissection or Aneurysm in Patients With Metastatic Colorectal Cancer."],"pmcid":["PMC12679322"],"pubmed_authors":["Jarne Munoz A","Pariente A","Noize P","Maumus-Robert S","Singier A","Berard X","Bezin J","Kempf E"],"additional_accession":[]},"is_claimable":false,"name":"Angiogenesis Inhibitors and Arterial Dissection or Aneurysm in Patients With Metastatic Colorectal Cancer.","description":"<h4>Importance</h4>Although pharmacovigilance signals and a strong pathophysiological rationale have suggested a potential risk of arterial dissections or aneurysms associated with angiogenesis inhibitors, this association deserves to be further investigated through clinical practice evidence studies.<h4>Objective</h4>To evaluate the association between exposure to angiogenesis inhibitors and the occurrence of arterial dissections or aneurysms in patients treated for metastatic colorectal cancer (mCRC).<h4>Design, setting, and participants</h4>A nested case-control study was conducted within a cohort of adults initiating targeted therapy (angiogenesis or epidermal growth factor receptor inhibitors) for mCRC between January 1, 2012, and December 31, 2017. Data were analyzed from April 2021 ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-05T22:34:40.873Z","creation":"2026-05-23T03:08:48.616Z"},"accession":"S-EPMC12679322","cross_references":{"pubmed":["41343210"],"doi":["10.1001/jamanetworkopen.2025.46960"]}}